Clinical Trial: ALLIANCE A032201

ALLIANCE A032201

Status: New, Open

Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma – STRIKE

Eligible for screening study DCP 001